Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,421 to 1,440 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology. | BioData Min | 2020 | 33292385 | PubTator, text mining | PubMed |
| Withanolide-Type Steroids from Withania aristata as Potential Anti-Leukemic Agents. | Molecules | 2020 | 33291428 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). | Cancers (Basel) | 2020 | 33287224 | PubTator, text mining | PubMed |
| [Prognostic Value of CD123 in Acute Myeloid Leukemia Patients with Intermediate Risk in Normal Karyotype]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2020 | 33283714 | PubTator, text mining | PubMed |
| TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer. | Biomed Res Int | 2020 | 33282948 | PubTator, text mining | PubMed |
| Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation. | Front Genet | 2020 | 33281875 | PubTator, text mining | PubMed |
| Survival prediction in patients with colon adenocarcinoma via multi-omics data integration using a deep learning algorithm. | Biosci Rep | 2020 | 33258470 | PubTator, text mining | PubMed |
| Clinical Outcomes Based on Measurable Residual Disease Status in Patients with Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. | J Pers Med | 2020 | 33256157 | PubTator, text mining | PubMed |
| NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? | Int J Mol Sci | 2020 | 33255988 | PubTator, text mining | PubMed |
| [Analysis of immunophenotypes and expressions of non-myeloid antigens in acute myeloid leukemia]. | Nan Fang Yi Ke Da Xue Xue Bao | 2020 | 33243747 | PubTator, text mining | PubMed |
| LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms. | Int J Mol Sci | 2020 | 33238475 | PubTator, text mining | PubMed |
| Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era. | Blood Res | 2020 | 33232940 | PubTator, text mining | PubMed |
| Development and validation of a prognostic model for adult patients with acute myeloid leukaemia. | EBioMedicine | 2020 | 33232873 | PubTator, text mining | PubMed |
| miRNA-122-5p stimulates the proliferation and DNA synthesis and inhibits the early apoptosis of human spermatogonial stem cells by targeting CBL and competing with lncRNA CASC7. | Aging (Albany NY) | 2020 | 33231565 | PubTator, text mining | PubMed |
| Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. | Blood Cancer J | 2020 | 33230098 | PubTator, text mining | PubMed |
| Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. | Front Oncol | 2020 | 33224890 | PubTator, text mining | PubMed |
| Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. | J Hematol Oncol | 2020 | 33213500 | PubTator, text mining | PubMed |
| RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. | Sci Rep | 2020 | 33208771 | PubTator, text mining | PubMed |
| Regulatory microRNAs in Brown, Brite and White Adipose Tissue. | Cells | 2020 | 33207733 | PubTator, text mining | PubMed |
| Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1. | Hemasphere | 2020 | 33204999 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=72